$SNDX

2 stories mentioning SNDXUpdated 47d ago

Every FINWIRES story that references SNDX, newest first.

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing

Michael A Metzger, Director, Chief Executive Officer, on July 08, 2026, sold 32,375 shares in Syndax Pharmaceuticals (SNDX) for $784,776. Following the Form 4 filing with the SEC, Metzger has control over a total of 484,843 common shares of the company, with 484,843 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395937/000119312526299803/xslF345X05/ownership.xml

$SNDX

Wire104d ago

UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating

Syndax Pharmaceuticals (SNDX) has an average rating of buy and mean price target of $39.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $20.29, Change: $-0.12, Percent Change: -0.59%

$SNDX

Track with the FINWIRES app suite

FolioX

Track SNDX in your portfolio

WheelAI

Analyze SNDX options with the wheel strategy

StockInsider

See market sentiment on SNDX